



## **Neuromed President & CEO Dr. Christopher Gallen Named Finalist for Scrip Award's "Executive of the Year"**

**CONSHOHOCKEN, PA and VANCOUVER, BC – October 5, 2007** – Neuromed Pharmaceuticals, a biopharmaceutical company developing new and improved chronic pain drugs, is pleased to announce its President & CEO, Dr. Christopher Gallen, has been named a finalist for a 2007 Scrip Award in the category of "Executive of the Year." Winners will be announced at the Scrip's award ceremony in London, UK, on December 4<sup>th</sup>. For more information on this award visit: <http://www.scripawards.com/>

Scrip's Executive of the Year award acknowledges excellence in the leadership of large and small pharmaceutical and biotechnology companies. This year's winner will be the executive who has displayed exemplary leadership throughout the year from June 1, 2006 to May 31, 2007. Also important to the judges will be the executive's career achievements, scientific contribution, influence within the industry and leadership qualities.

### **About Christopher C. Gallen, MD, PhD**

Dr. Gallen brings to Neuromed an extensive track record in clinical and corporate development and has been instrumental in the commercialization of several drugs. Prior to joining Neuromed in July 2004, Dr. Gallen was Vice President and Chief of Operations, Clinical Research and Development at Wyeth Research in charge of global clinical operations including clinical trial management, data management, biostatistics, clinical communications, procedural compliance and training and was a key driver in the re-engineering of Wyeth Clinical Research and Development. Prior to Wyeth, Dr. Gallen was VP of Clinical Research at Pharmacia and was responsible for overseeing global CNS development and clinical operations for all specialties and clinical research in the Western Hemisphere. Previous positions include President of the CRO division at Premier Research Worldwide, where he was a key contributor to a successful IPO, and Senior Director of Medical and Scientific Services at Quintiles International Clinical Research Corporation. Dr. Gallen received his M.D. and Ph.D. (Biochemistry) from the Emory University School of Medicine in Atlanta, Georgia and completed residencies in Psychiatry at Stanford and in Neurology at UCSD.

### **About Neuromed**

Neuromed is a privately held biopharmaceutical company in business to develop new and improved pain medicines. We have three programs aimed at addressing this important unmet medical need. Neuromed acquired the U.S. marketing rights to OROS<sup>®</sup> Hydromorphone (NMED-1077), an extended release formulation of hydromorphone in Phase 3 clinical development. Neuromed is also developing oral drug candidates to block N-type calcium channels, a novel target directly involved in pain signaling. Our third program of T-type calcium channel blockers is producing promising compounds aimed at treating pain, epilepsy and hypertension. For more information visit [www.neuromed.com](http://www.neuromed.com).

###

**For more information regarding this press release, contact:**

Julie Jang  
Director, Communications  
Neuromed Pharmaceuticals  
Phone: (604) 909-2547  
Email: [jjang@neuromed.com](mailto:jjang@neuromed.com)

[Neuromed Pharmaceuticals Ltd.](http://www.neuromed.com)

[www.neuromed.com](http://www.neuromed.com)